HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (14) Citing Articles via Google Scholar Google Scholar Articles by Tzekov, R. Articles by Burke, J. Search for Related Content PubMed PubMed Citation Articles by Tzekov, R. Articles by Burke, J.

Ocular Changes after Photodynamic Therapy

¹From the Departments of Biological Sciences and ²Safety Evaluation, Allergan Inc., Irvine, California; and the ³Department of Ophthalmology, University of California at Irvine, Irvine, California.

PURPOSE. The aim of this study was to identify the changes in the primate visual system after a single session of photodynamic therapy (PDT) in an intact nonhuman primate retina.

METHODS. As part of a larger study, PDT (wavelength 689 nm, 50 J/cm², 600 mW/cm², 83 seconds, 4-mm spot size) with verteporfin (6 mg/m² intravenous infusion) was performed in one eye each of two cynomolgus monkeys. Fundus photography, fluorescein angiography (FA), indocyanine green angiography (ICG), optical coherence tomography (OCT), and multifocal electroretinography (mfERG) were performed at baseline and 12 time points (1–283 days) after PDT. In addition, retinal histopathologic findings were evaluated at 9 months.

RESULTS. Various morphologic changes, including whitening of the treated area, RPE proliferation, closure of the choroidal vasculature, and subretinal edema (followed by foveolar thinning) were observed. Most of the changes persisted and were detectable in histopathologic evaluation at 9 months. Reductions of the mfERG amplitude, followed by varying degrees of recovery from the treated and the border regions, were observed. This was accompanied by progressive delay of P1 peak time up to 3 months after treatment, followed by complete recovery at 9 months. In addition, the nontreated area showed amplitude and timing mfERG deficits, which underwent gradual (but not complete) recovery.

CONCLUSIONS. In a primate model, under standard clinical parameters, a single PDT treatment resulted in various dynamic morphologic and functional retinal changes detectable for up to 9 months after treatment. The significance of the observed changes and possible ways of pharmacologic interference with PDT adverse effects are discussed.

This article has been cited by other articles:

				M. Berdugo, R. A. Bejjani, F. Valamanesh, M. Savoldelli, J.-C. Jeanny, D. Blanc, H. Ficheux, A. Scherz, Y. Salomon, D. BenEzra, et al. Evaluation of the New Photosensitizer Stakel (WST-11) for Photodynamic Choroidal Vessel Occlusion in Rabbit and Rat Eyes Invest. Ophthalmol. Vis. Sci., April 1, 2008; 49(4): 1633 - 1644. [Abstract] [Full Text] [PDF]

				S J Kang, I Schmack, H E Benson, and H E Grossniklaus Histopathological findings in postmortem eyes after photodynamic therapy for choroidal neovascularisation in age-related macular degeneration: report of two cases Br. J. Ophthalmol., December 1, 2007; 91(12): 1602 - 1606. [Abstract] [Full Text] [PDF]

				Z. F. Bashshur, A. Schakal, R. N. Hamam, C. P. El Haibi, R. F. Jaafar, and B. N. Noureddin Intravitreal Bevacizumab vs Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration Arch Ophthalmol, October 1, 2007; 125(10): 1357 - 1361. [Abstract] [Full Text] [PDF]

				K. Ishikawa, M. Kondo, Y. Ito, M. Kikuchi, H. Nishihara, C.-H. Piao, T. Sugita, and H. Terasaki Correlation between Focal Macular Electroretinograms and Angiographic Findings after Photodynamic Therapy Invest. Ophthalmol. Vis. Sci., May 1, 2007; 48(5): 2254 - 2259. [Abstract] [Full Text] [PDF]

				H. She, T. Nakazawa, A. Matsubara, T. Hisatomi, T. A. Young, N. Michaud, E. Connolly, A. Hafezi-Moghadam, E. S. Gragoudas, and J. W. Miller Reduced Photoreceptor Damage after Photodynamic Therapy through Blockade of Nitric Oxide Synthase in a Model of Choroidal Neovascularization Invest. Ophthalmol. Vis. Sci., May 1, 2007; 48(5): 2268 - 2277. [Abstract] [Full Text] [PDF]

				W.-M. Chan, T. Y Y Lai, A. L Wong, D. T L Liu, and D. S C Lam Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study Br. J. Ophthalmol., February 1, 2007; 91(2): 174 - 179. [Abstract] [Full Text] [PDF]

				I Kozak, L Cheng, D E Cochran, and W R Freeman Phase I clinical trial results of verteporfin enhanced feeder vessel therapy in subfoveal choroidal neovascularisation in age related macular degeneration Br. J. Ophthalmol., September 1, 2006; 90(9): 1152 - 1156. [Abstract] [Full Text] [PDF]

				T Y Y Lai, W-M Chan, H Li, R Y K Lai, D T L Liu, and D S C Lam Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study Br. J. Ophthalmol., July 1, 2006; 90(7): 869 - 874. [Abstract] [Full Text] [PDF]